Stemgent Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Stemgent Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013245
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Stemgent Inc (Stemgent), a part of the ReproCELL Group is a biotechnology company that focuses on the development of innovative technology and application solutions for the advancement of stem cell research. The company’s product portfolio comprises antibodies, cell lines, cytokines / proteins, differentiation, matrices, media, reprogramming systems, small molecules and transfection. It also offers iPS cell services and training courses for research scholars of various research laboratories. These training courses cover all essential protocols for lentiviral and mRNA reprogramming and human induced pluripotent (iPS) cell culture techniques in a hands-on laboratory environment. The company operates research sites in Cambridge, Massachusetts and San Diego, California. Stemgent is headquartered in Cambridge, Massachusetts, the US.

Stemgent Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Stemgent Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Stemgent Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Stemgent Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Stemgent Inc, Medical Devices Deals, 2011 to YTD 2017 8
Stemgent Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Stemgent Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Stemgent Completes Acquisition Of Human Tissue Business From Asterand For US$9 Million 10
Venture Financing 12
Stemgent Raises US$11.3 Million In Venture Financing 12
Stemgent Raises US$6.3 Million In Series C Financing 13
Stemgent Secures US$0.58 Million In Venture Financing 14
Stemgent Secures US$0.75 Million In Venture Financing 15
Partnerships 16
ATCC Enters Into Co-Development Agreement With Stemgent 16
Licensing Agreements 17
Stemgent Enters Into Licensing Agreement With iPS Academia For Induced Pluripotent Stem Cell Patent Portfolio 17
Asset Transactions 18
ReproCELL Acquires Induced Pluripotent Stem Cell Business from Stemgent for USD8.5 Million 18
Stemgent Inc – Key Competitors 19
Stemgent Inc – Key Employees 20
Stemgent Inc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Stemgent Inc, Pharmaceuticals & Healthcare, Key Facts 2
Stemgent Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
Stemgent Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Stemgent Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Stemgent Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Stemgent Inc, Medical Devices Deals, 2011 to YTD 2017 8
Stemgent Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Stemgent Completes Acquisition Of Human Tissue Business From Asterand For US$9 Million 10
Stemgent Raises US$11.3 Million In Venture Financing 12
Stemgent Raises US$6.3 Million In Series C Financing 13
Stemgent Secures US$0.58 Million In Venture Financing 14
Stemgent Secures US$0.75 Million In Venture Financing 15
ATCC Enters Into Co-Development Agreement With Stemgent 16
Stemgent Enters Into Licensing Agreement With iPS Academia For Induced Pluripotent Stem Cell Patent Portfolio 17
ReproCELL Acquires Induced Pluripotent Stem Cell Business from Stemgent for USD8.5 Million 18
Stemgent Inc, Key Competitors 19
Stemgent Inc, Key Employees 20
Stemgent Inc, Other Locations 21

★海外企業調査レポート[Stemgent Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Eli Lilly and Co (LLY)-医療機器分野:企業M&A・提携分析
    Summary Eli Lilly and Company (Lilly) is a healthcare company that discovers, develops and markets human and animal healthcare products. The company offers medicines for cardiovascular conditions, diabetes, cancer, neurological problems, critical care, men's health and musculoskeletal problems. It a …
  • Ameresco Inc (AMRC):電力:M&Aディール及び事業提携情報
    Summary Ameresco, Inc. (Ameresco) provides comprehensive energy services, including energy efficiency, infrastructure upgrades, asset sustainability and renewable energy solutions. It also offers energy infrastructure facility upgrade; and development, construction and operation of renewable energy …
  • Poxel SA (POXEL):企業の財務・戦略的SWOT分析
    Summary Poxel SA (Poxel) is a biopharmaceutical company that focuses to develop drugs for metabolic diseases. The company’s pipeline product portfolio includes Imeglimin, which is developed to target mitochondrial dysfunction, for the treatment of type 2 diabetes; PXL065, a mitochondrial pyruvate ca …
  • Lincoln Electric Cooperative Inc:企業の戦略的SWOT分析
    Lincoln Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • New Age (African Global Energy) Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary New Age (African Global Energy) Ltd (New Age) is an oil and gas company that explores and develops oil and gas fields, and oil wells. The company provides activities such as include exploration, production, appraisal and development of oil and gas assets in seven sub Saharan African countrie …
  • ConocoPhillips (COP):企業の財務・戦略的SWOT分析
    ConocoPhillips (COP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • VentriPoint Inc:製品パイプライン分析
    Summary VentriPoint Inc (VentriPoint), a subsidiary of VentriPoint Diagnostics Ltd is a medical device company that manufactures and distributes medical devices for the cardiovascular market. The company’s product VMS is a heart visualization system which is used to evaluate right heart function. It …
  • Porton Pharma Solutions Ltd (300363):企業の財務・戦略的SWOT分析
    Summary Porton Pharma Solutions Ltd (Porton) is involved in the supply of intermediate drugs and active pharmaceutical ingredients. The company provides custom and contract chemical development, and contract manufacturing services. It is also involved in providing research and development and produc …
  • Allianz Insurance plc:企業の戦略・SWOT・財務情報
    Allianz Insurance plc - Strategy, SWOT and Corporate Finance Report Summary Allianz Insurance plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Eindec Corporation Ltd (42Z):企業の財務・戦略的SWOT分析
    Eindec Corporation Ltd (42Z) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Canon Marketing Japan Inc (8060):企業の財務・戦略的SWOT分析
    Canon Marketing Japan Inc (8060) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • GPS Source, Inc.:企業の戦略・SWOT・財務情報
    GPS Source, Inc. - Strategy, SWOT and Corporate Finance Report Summary GPS Source, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Huadian Power International Corporation Ltd (1071):電力:M&Aディール及び事業提携情報
    Summary Huadian Power International Corporation Ltd (HPICL) is an electric utility. It constructs and operates power plants, including coal- or gas-fired generating units and renewable energy projects. The company has plants at the electricity and heat load centers or regions with abundant coal reso …
  • African Development Bank Group:企業の戦略的SWOT分析
    African Development Bank Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Japan Pulp and Paper Company Limited:企業の戦略・SWOT・財務情報
    Japan Pulp and Paper Company Limited - Strategy, SWOT and Corporate Finance Report Summary Japan Pulp and Paper Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • ThyssenKrupp AG:企業の戦略・SWOT・財務情報
    ThyssenKrupp AG - Strategy, SWOT and Corporate Finance Report Summary ThyssenKrupp AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Zeria Pharmaceutical Co Ltd (4559):製薬・医療:M&Aディール及び事業提携情報
    Summary Zeria Pharmaceutical Co Ltd (Zeria), formerly Zeria Yakusho Kenkyusho Co Ltd is a pharmaceutical company that manufactures pharmaceutical and non-pharmaceuticals, veterinary pharmaceuticals, industrial chemicals and reagents. The company imports and exports healthcare products such as cosmet …
  • Tulip Diagnostics (P) Ltd-医療機器分野:企業M&A・提携分析
    Summary Tulip Diagnostics (P) Ltd (Tulip Diagnostics), a subsidiary of Tulip Group is a diagnostic company that manufactures and markets in vitro diagnostic reagents and kits for the medical markets. The company provides assay systems for immunohaematology, hematology, rheumatology, infectious disea …
  • Europa Oil & Gas (Holdings) plc (EOG):企業の財務・戦略的SWOT分析
    Summary Europa Oil & Gas (Holdings) Plc (Europa Oil) is an oil and gas company that offers exploration and development services. The company offers services such as production and development of conventional and unconventional hydrocarbon assets. It operates its assets in East Midlands basin, Aquita …
  • Swedbank AB:企業の戦略・SWOT・財務分析
    Swedbank AB - Strategy, SWOT and Corporate Finance Report Summary Swedbank AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆